Company* |
Company* |
Product | Terms/Details (Date) |
| | |||
Acadia |
Amarin Development AB (Sweden; subsidiary of Amarin Corp. plc; UK; AMRN) |
ACP-103 |
Amarin will provide pharmaceutical formulation and manufacturing services for Acadia; ACP- 03 is in Phase I studies for neuropsychiatric and neurological disorders (6/18) |
|
|
|
|
Aclara |
Research and Diagnostic |
R&D System's reagents with Aclara's eTag Assay System |
R&D Systems will supply Aclara with certain reagents, including cytokines and related proteins and antibodies that are being incorporated into the eTag Assay System (5/21) |
|
|
|
|
Agencourt Biosciences |
Lucigen Corp.* |
CloneSmart cloning kits and research products |
Agencourt will distribute Lucigen's kits and products in North America; Lucigen will continue to sell directly to those markets; it transferred to Agencourt certain new product rights arising from its Single Cell Genomics gene discovery libraries in return for in-kind genomic sequencing services provided by Agencourt and undisclosed financial payments (5/27) |
|
|
|
|
BD Biosciences (unit of Becton, Dickinson and Co.; NYSE:BDX) |
Open Biosystems* |
BD Creator gene cloning and expression system |
Open Biosystems was granted a worldwide, nonexclusive license to make, use and sell clone sets in the BD Creator technology format (5/14) |
|
|
|
|
Boston Biomedica Inc. (BBII) |
Ambion RNA Diagnostics* |
Ambion's Armored RNA and RunReady products |
Boston Biomedica will sell the products through its diagnostics unit (4/29) |
|
|
|
|
Cellegy Pharmaceuticals Inc. (CLGY) |
Neopharm Ltd.* (Israel) |
Tostrex gel |
Neopharm will be the exclusive distributor of Tostrex gel in Israel; it also will file for approval using an existing regulatory package supplied by Cellegy (5/28) |
|
|
|
|
Hawaii Biotech Inc.* Meridian Bioscience |
Viral Antigens Inc. (subsidiary of dengue Inc.; VIVO) |
Bulk polyvalent recombinant subunit vaccine for virus 1-4 |
Viral Antigens will manufacture and supply the vaccine (6/10) |
|
|
|
|
InKine Pharmaceutical |
Paladin Labs Inc. (Canada; TSE:PLB) |
Visicol |
Paladin Labs licensed the exclusive rights to register, sell, market and distribute Visicol for use in Canada; Paladin paid an undisclosed up-front license fee and will pay royalties to InKine on future sales of Visicol; Paladin will be responsible for all costs (5/21) |
|
|
|
|
MDS Sciex |
SC BioSciences Corp.* (Japan) |
NanoLC Proteomics |
Exclusive distributorship agreement to deliver MDS Sciex's NanoLC Proteomics system in Japan (6/9) |
|
|
|
|
Nastech Pharmaceutical |
Questcor Pharmaceuticals Inc. (AMEX:QSC) |
Nascobal |
Questcor is paying up to $18.2M for rights to the approved drug Nascobal, a product for multiple sclerosis and inflammatory bowel disease (6/17) |
|
|
|
|
NovaScreen Biosciences Corp.* |
Tripos Inc. (TRPS) |
Tripos' LeadScreen compound plates and LeadQuest libraries; NovaScreen's assay development, HTS reagents, HTS services, secondary screening and in vitro ADME/Tox screening |
Mutual service and distribution agreement that will allow each company's sales force to offer the other's products and services to its biotechnology and pharmaceutical clients (6/18) |
|
|
|
|
Orchid BioSciences Inc. (ORCH) |
Genetic Technologies Ltd. (Australia; OTC BB: GNTLF; ASX:GTG) |
Exclusive licensing agreement for Orchid's SNP panels for paternity and forensic DNA testing services for Australia, New Zealand and Southeast Asia |
Genetic Technologies also receives an exclusive license to market, distribute and sell Orchid's Elucigene range of diagnostic kits for genetic testing in those territories, as well as a nonexclusive license in the field of diagnostics to certain primer extension patents; Orchid receives an option to license Genetic Technologies' non-coding patents for SNP analysis; it will receive royalties on revenues generated from its SNP-based technologies (5/30) |
|
|
|
|
OSI Pharmaceuticals Inc. (OSIP) |
Celgene Corp. (CELG) |
Gelclair |
OSI gained full rights to market and promote Gelclair in the North American oncology setting; it gained the rights through its acquisition of Cell Pathways Inc., which had a co-promotion agreement with Celgene (6/13) |
|
|
|
|
PamGene International BV* (the Netherlands) |
Olympus Optical Co. Ltd.* (Japan) |
PamGene's flow-through microarray technology |
Olympus paid |6M (US$7M) for the nonexclusive worldwide right to sell the product (5/7) |
|
|
|
|
Pharmasset Inc.* |
Primagen Holding BV* (the Netherlands) |
A mitochondrial DNA detection and toxicity technology |
The agreement is for an exclusive worldwide license to commercialize the technology developed by Pharmasset (4/28) |
|
|
|
|
Pharmexa A/S (Denmark; CSE:PHARMX) |
Xenova Group plc (UK; XNVA; LSE:XEN) |
A vaccine targeting the human HER-2 protein |
Xenova signed a two-year manufacturing, development and clinical supply agreement with Pharmexa for the contract manufacture of clinical supplies of the vaccine (6/5) |
|
| |||
Notes: | |||
# The information in the chart does not cover agricultural agreements. | |||
* Private companies are indicated with an asterisk. | |||
Unless otherwise noted, stock symbols listed are on the Nasdaq market. | |||
AMEX = American Stock Exchange; CSE = Copehnhagen Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; TSE = Toronto Stock Exchange. | |||
